
Jorge E. Cortes, MD, presents data from a dose ranging study of ponatinib in patients with chronic-phase chronic myeloid leukemia.
Your AI-Trained Oncology Knowledge Connection!
Jorge E. Cortes, MD, presents data from a dose ranging study of ponatinib in patients with chronic-phase chronic myeloid leukemia.
Hematologic oncologists summarize the dose ranging study of ponatinib in patients with CML and discuss clinical implications of this work.
Dr. Cortes reviews ponatinib dosing strategies based on patient profiles and mutational status.
Hagop Kantarjian, MD responds to a review of dosing options in patients with CML treated with ponatinib.
Jorge E. Cortes, MD and Hagop Kantarjian, MD debate optimal dosing and discuss how they use ponatinib in patients with CML.
Experts review future implications such as using ponatinib in earlier lines of therapy and in patients with Ph-positive ALL.
Jorge E. Cortes, MD and Hagop Kantarjian, MD share a summary on ponatinib in CML and ALL and exploration of potential future studies.
Experts discuss use of ponatinib in chronic myeloid leukemia and optimal dosing.